Physician profile
Herrera Danilo
NPI 1427005206
$6,908.83
in general payments reported to CMS, 2019-2025
27 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,479 · 2020: $362 · 2021: $372 · 2022: $337 · 2023: $73.08 · 2024: $70.97 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,000 · Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,000.00 |
| Food and Beverage | $359.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,078.94 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $1,394.69 | 2019 | |
| Abbvie INC. | $1,049.92 | 2019-2022 | |
| Coloplast Corp | $682.04 | 2019-2020 | |
| Hologic Sales and Service, LLC | $406.51 | 2019-2025 | Aptima, Myosure Tissue Removal Device |
| Amgen INC. | $302.29 | 2019-2021 | |
| Pfizer INC. | $256.80 | 2019-2025 | |
| Astellas Pharma US INC | $196.16 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $89.93 | 2023-2025 | |
| Allergan, INC. | $69.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.10 | 2019-2024 | |
| Baxter Healthcare | $60.98 | 2021-2024 | Perclot |
| Mylan Pharmaceuticals INC. | $57.38 | 2021-2022 | |
| Organon LLC | $42.03 | 2022-2025 | Jada System |
| Therapeuticsmd, INC. | $25.81 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $16.21 | 2023 | Pico 14 |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2022 | |
| Duchesnay USA Incorporated | $14.53 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.69 | 2019 | |
| Endo Pharmaceuticals INC. | $13.22 | 2019 | |
| Boston Scientific Corporation | $13.19 | 2019 | |
| Evofem Biosciences, INC. | $13.18 | 2025 | Phexxi, Solosec, Phexx |
| Daiichi Sankyo INC. | $12.93 | 2019 | |
| Myovant Sciences INC. | $11.66 | 2022 | |
| Novo Nordisk INC | $11.32 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herrera Danilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.